PMID- 15993840
OWN - NLM
STAT- MEDLINE
DCOM- 20050915
LR  - 20181201
IS  - 0006-291X (Print)
IS  - 0006-291X (Linking)
VI  - 334
IP  - 1
DP  - 2005 Aug 19
TI  - Rational design of an EGF-IL18 fusion protein: implication for developing tumor 
      therapeutics.
PG  - 157-61
AB  - Interleukin-18 (IL-18) is a proinflammatory cytokine. This protein has a role in 
      regulating immune responses and exhibits significant anti-tumor activities. 
      Epidermal growth factor (EGF) is an important growth factor that plays a central 
      role in the regulation of cell cycle and differentiation. It was proposed that a 
      targeted delivery of IL-18 by generation of IL-18-EGF fusion protein might 
      decrease adverse effects and result in enhancing cytotoxic and antitumor 
      activities. In the present study, a fusion protein, consisting of EGFR binding 
      domain fused to human IL-18 mature peptide via a linker peptide of (Gly(4)Ser) 3, 
      was constructed and expressed in the insect cell line Sf9 using Bac-to-Bac 
      baculovirus expression system. We showed that the purified recombinant fusion 
      protein induced similar levels of IFN-gamma to that of native IL-18 protein in 
      human PBMC in the presence of ConA. Furthermore, EGF receptor competitive test in 
      human epithelial cancer A431 cell line showed that EGF-IL18 fusion protein can 
      specifically bind with EGFR by competing with native EGF protein. These suggest 
      that this rationally designed protein can be further developed as novel tumor 
      therapeutics.
FAU - Lu, Jian-Xin
AU  - Lu JX
AD  - Institute of Cellular and Molecular Medicine, School of Laboratory Medicine, 
      Wenzhou Medical College, Wenzhou, Zhejiang 325035, China.
FAU - Peng, Ying
AU  - Peng Y
FAU - Meng, Zhe-Feng
AU  - Meng ZF
FAU - Jin, Li-Qin
AU  - Jin LQ
FAU - Lu, Yong-Sui
AU  - Lu YS
FAU - Guan, Min-Xin
AU  - Guan MX
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Biochem Biophys Res Commun
JT  - Biochemical and biophysical research communications
JID - 0372516
RN  - 0 (Interleukin-18)
RN  - 0 (Recombinant Fusion Proteins)
RN  - 62229-50-9 (Epidermal Growth Factor)
RN  - EC 2.7.10.1 (ErbB Receptors)
SB  - IM
MH  - Animals
MH  - Carcinoma, Squamous Cell/genetics/*metabolism/therapy
MH  - Cell Line
MH  - Drug Delivery Systems/*methods
MH  - *Drug Design
MH  - Epidermal Growth Factor/genetics/*metabolism/therapeutic use
MH  - ErbB Receptors/*metabolism
MH  - Gene Targeting/*methods
MH  - Humans
MH  - Interleukin-18/genetics/*metabolism/therapeutic use
MH  - Protein Engineering/*methods
MH  - Recombinant Fusion Proteins/metabolism
MH  - Spodoptera/genetics/*metabolism
MH  - Transfection/methods
EDAT- 2005/07/05 09:00
MHDA- 2005/09/16 09:00
CRDT- 2005/07/05 09:00
PHST- 2005/05/17 00:00 [received]
PHST- 2005/06/13 00:00 [accepted]
PHST- 2005/07/05 09:00 [pubmed]
PHST- 2005/09/16 09:00 [medline]
PHST- 2005/07/05 09:00 [entrez]
AID - S0006-291X(05)01267-2 [pii]
AID - 10.1016/j.bbrc.2005.06.076 [doi]
PST - ppublish
SO  - Biochem Biophys Res Commun. 2005 Aug 19;334(1):157-61. doi: 
      10.1016/j.bbrc.2005.06.076.